For patients with cancers that have resisted conventional systemic therapies, the ability to simultaneously image and destroy tumor cells using the same molecular target represents a genuine paradigm shift — one that is rapidly expanding beyond its original foothold in rare neuroendocrine and prostate cancers.
Radiotheranostics pairs a diagnostic radiopharmaceutical with a therapeutic counterpart that shares the same targeting ligand, allowing oncologists to confirm target expression before delivering lethal radiation directly to tumor cells. The field's clinical foundation rests on two landmark agents: Lutetium-177-DOTATATE, which targets somatostatin receptors in neuroendocrine tumors, and Lutetium-177-PSMA-617, which homes to prostate-specific membrane antigen in metastatic castration-resistant prostate cancer — both validated in randomized controlled trials. The review in BMJ Oncology charts the next wave: platforms directed at fibroblast activation protein (FAP), which is overexpressed in tumor-associated stroma across numerous solid malignancies, and other lineage-associated receptor systems, dramatically widening the addressable cancer landscape. On the radiochemistry frontier, alpha-particle emitters are emerging as high-potency alternatives to beta-emitters, offering denser ionization tracks that may prove decisive against small-volume and micrometastatic disease where beta-particle path lengths can miss individual cells. Engineering advances — including half-life-extended ligands and multivalent constructs — are designed to maximize tumor residence time while limiting off-target dose.
The shift from empiric, population-average dosing to individualized, voxel-level dosimetry enabled by quantitative imaging and AI-driven workflows represents perhaps the most clinically consequential near-term development. Historically, radiotheranostics has delivered fixed activity doses, a pragmatic but imprecise approach. Personalized dosimetry could optimize efficacy while reducing toxicity to kidneys and bone marrow — the dose-limiting organs in most protocols. The field remains constrained by limited radiopharmaceutical manufacturing infrastructure, high treatment costs, and the need for specialized multidisciplinary teams. Nevertheless, this review signals that radiotheranostics is transitioning from niche specialty to a broadly applicable precision oncology platform, with AI integration potentially enabling the scale required for mainstream adoption.